Preserve instead of repair
is the philosophy of Dr Tatjana Pavicic MD

“By this I mean that patients who want to preserve their youthful appearance for a long time should start early with smaller treatsments. Most patients come at an age when the facial expressions already pronounced and the bothersome wrinkles are clearly visible. My aim is to make dealing with aesthetic treatments more a matter of course and to avoid the larger, more expensive interventions. The earlier slight corrections are undertaken, the more natural, the longer lasting and the more cost-effective the results are for the patients.”

The anatomy of a face, the speaking pattern, the proportions and the overall shape and expression are important for Dr Tatjana Pavicic. “I analyse each patient individually and as a doctor I establish a diagnosis and appropriate treatment plan before each treatment.”

Dr Pavicic is a medical specialist in dermatology and venereology with her own practice in Munich. She is an internationally leading expert in aesthetic dermatology with a specific focus on botulinum toxin, fillers, laser and energy-based devices and cosmeceuticals.

Dr Pavicic is a member of several national and international dermatological and cosmetic societies. She is the General Secretary of the International Peeling Society, board member of the International Society for Derm Surgery and IMCAS academy.

Dr Pavicic has published numerous articles in national and international scientific journals in the field of classical and aesthetic dermatology and has also conducted clinical studies in aesthetic dermatology and minimally invasive aesthetic surgery.

Hautärzte (Dermatologen)
in München auf jameda

Other activities

Publications

  • Pavicic T, Webb KL, Frank K, Gotkin RH, Tamura B, Cotofana S (2018)
    Arterial Wall Penetration Forces in Needle vs. Cannula. Accepted Plast Reconstr Surg.
  • Frank K, Koban K, Targosinski S, Erlbacher K, Schenck TL, Casabona G, Braz AV, Pavicic T, Cotofana S. (2018)
    The Anatomy behind Adverse Events in Hand Volumizing Procedures: Retrospective Evaluations of 11 Years of Experience. Plast Reconstr Surg. 2018 May;141(5):650e-662e.
  • Pavicic T, Frank K, Erlbacher K, Neuner R, Targosinski S, Schenck T, Gotkin RH, Cotofana S. (2017)
    Precision in Dermal Filling: A Comparison Between Needle and Cannula When Using Soft Tissue Fillers. J Drugs Dermatol. 2017;16(9):866-872.
  • Fabi S, Pavicic T, Braz A, Green JB, Seo K, van Loghem JA. (2017)
    Combined aesthetic interventions for prevention of facial ageing, and restoration and beautification of face and body. Clin Cosmet Investig Dermatol. 2017;10:423-429
  • Gout U, Anand CV, Braz A, Chao YYY, Fabi SG, Kerscher M, Landau M, Pavicic T, Peng PHL, Rzany B, Sattler G, Tiryaki T, Waldorf HA, Besins T. (2017)
    Communication Concepts for Prevention and Early Intervention in Aesthetic Medicine: Consensus and Literature Review. J Drugs Dermatol. 2017;16(9):859-864.
  • Landau M, Anand CV, Besins T, Chao YYY, Fabi SG, Gout U, Kerscher M, Pavicic T, Peng PHL, Rzany B, Sattler G, Tiryaki T, Waldorf HA, Braz A. (2017)
    First Consensus on Primary Prevention and Early Intervention in Aesthetic Medicine. J Drugs Dermatol. 2017;16(9):846-854.
  • Chao YYY, Chhabra C, Corduff N, Fabi SG, Kerscher M, Lam SCK, Pavicic T, Rzany B, Peng PHL, Suwanchinda A, Tseng FW, Seo KK. PAN-ASIAN CONSENSUS-Key Recommendations for Adapting the World Congress of Dermatology Consensus on Combination Treatment with Injectable Fillers, Toxins, and Ultrasound Devices in Asian Patients. J Clin Aesthet Dermatol. 2017;10(8):16-27.
  • Cotofana S, Mian A, Sykes JM, Redka-Swoboda W, Ladinger A, Pavicic T, Schenck TL, Benslimane F, Ingallina F, Schlattau A. (2017)
    An Update on the Anatomy of the Forehead Compartments.
    Plast Reconstr Surg. 2017 Apr;139(4):864e-872e
  • Fabi SG, Burgess C, Carruthers A, Carruthers J, Day D, Goldie K, Kerscher M, Nikolis A, Pavicic T, Rho NK, Rzany B, Sattler S, Seo K, Werschler WP, Sattler G. (2016)
    Consensus Recommendations for Combined Aesthetic Interventions Using Botulinum Toxin, Fillers, and Microfocused Ultrasound in the Neck, Décolletage, Hands, and Other Areas of the Body. Dermatol Surg. 2016 Oct;42(10):1199-1208.
  • Cotofana S, Fratila AA, Schenck TL, Redka-Swoboda W, Zilinsky I, Pavicic T. (2016)
    The Anatomy of the Aging Face: A Review. Facial Plast Surg. Jun;32(3):253-60.
  • Black JM, Pavicic T, Jones DH. (2016)
    Tempering Patient Expectations and Working With Budgetary Constraints When It Comes to a Single Versus a Multimodal Approach.
    Dermatol Surg. May;42 Suppl 2:S161-4.
  • Carruthers J, Burgess C, Day D, Fabi SG, Goldie K, Kerscher M, Nikolis A, Pavicic T, Rho NK, Rzany B, Sattler G, Sattler S, Seo K, Werschler WP, Carruthers A. (2016)
    Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg. May;42(5):586-97.
  • Pavicic T, Prager W, Klöppel M, Ravichandran S, Galatoire O. (2015)
    Incobotulinumtoxina use in aesthetic indications in daily practice: a european multicenter, noninterventional, retrospective study. Clin Cosmet Investig Dermatol. 5;8:135-42
  • Funt D, Pavicic T. (2015)
    Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Plast Surg Nurs. 35(1):13-32
  • Pavicic T. (2015)
    Complete biodegradable nature of calcium hydroxylapatite after injection for malar enhancement: an MRI study. Clin Cosmet Investig Dermatol. 9;8:19-25
  • Maier T, Flaig MJ, Ruzicka T, Berking C, Pavicic T. (2015)
    High-definition optical coherence tomography and reflectance confocal microscopy in the in vivo visualization of a reaction to permanent make-up. J Eur Acad Dermatol Venereol. 29(3):602-6
  • Proebstle TM, Chung G, Weissberg R, Pavicic T. (2014)
    Quantitative evaluation of the onset and longevity of the action of incobotulinumtoxinA by skin displacement analysis in the treatment of glabellar frown lines. J Drugs Dermatol 13(9): 1067-72.
  • Rzany B, Fratila AA, Fischer TC, Hilton S, Pavicic T, Rothhaar A, Sattler G, Sommer B, Pickett A. (2013)
    Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications. J Drugs Dermatol. 12: 80-4.
  • Funt D, Pavicic T (2013)
    Dermal fillers in esthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 12;6:295-316
  • Pavicic T. (2013)
    Calcium hydroxylapatite filler: an overview of safety and tolerability. J Drugs Dermatol. 12(9):996-1002.
  • Pavicic T, Few JW, Huber-Vorländer J (2012)
    A Novel, Multistep, Combination Facial Rejuvenation Procedure for Treatment of the Whole Face with Bocouture®, Radiesse® and Belotero®. Submitted to JDD
  • Gauglitz GG, Pavicic T. (2012)
    Emerging strategies for the prevention and therapy of excessive scars. MMW Fortschr Med. 10;154 :55-8
  • Pavicic T, Gauglitz GG (2012)
    Modern soft tissue augmentation–away from treating the single fold to volume replacement in the whole face. MMW Fortschr Med. 10;154:51-2, 54
  • Pavicic T, Gauglitz GG, Ruzicka T. (2012)
    Medicine for youth and beauty: smoothing folds and scars. MMW Fortschr Med. 10;154:50
  • Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. (2012)
    Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012;25(6):313-8
  • Prager W, Huber-Vorländer J, Taufig AZ, Imhof M, Kühne U, Weissberg R, Kuhr LP, Rippmann V, Philipp-Dormston WG, Proebstle TM, Roth C, Kerscher M, Ulmann C, Pavicic T (2012)
    Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice. Clin Cosmet Investig Dermatol. 5: 53-58
  • Pavicic T, Gauglitz GG, Lersch P, Schwach-Abdellaoui K, Malle B, Korting HC, Farwick M (2011)
    Efficacy of cream-based novel formulations of hyaluronic acid of different molecular size in anti-wrinkle treatment. JDD 10: 990-1000
  • Farwick M, Gauglitz G, Pavicic T, Köhler T, Wegemann M, Schwach-Abdellaoui K, Malle B, Tarabin V, Schmitz G, Korting HC (2011)
    50 kDa hyaluronic acid upregulates some epidermal genes without changing TNFalpha expression in reconstituted epidermis. Skin Phisiol Pharmacol 24:210-217
  • Pavicic T (2011)
    Efficacy and Tolerability of a New Monophasic Double Crosslinked Hyaluronic Acid Filler for Correction of Deep Lines and Wrinkles. JDD 10: 134-139
  • Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG (2011)
    Hypertrophic csarring and keloids: pathomechnisms and current and emerging treatment strategies. Mol Med 17: 113-125
  • Schröder S, Fietzek UM, Pavicic T, Stehr M, Baumann AC, Ruzicka T, Heinen F (2011)
    Allrounder Botulinumtoxin. Falten glätten, Schweiß stoppen, Spasmen lösen. MMW – Fortschritte der Medizin 153: 33-35
  • Pavicic T, Thomas P (2010)
    Comlications due to soft tissue implants (“filler”). BIOmaterialien 11: 37-41
  • Gauglitz GG, Pavicic T, Ruzicka T (2010)
    Management of hypertriphic scars and keloids. MMW Forschr Med. 152: 40-43
  • Pavicic T (2010)
    Falten glätten und Volumen geben: Was moderne Filler können. Ästhetische Dermatologie und Kosmetologie 2: 33-39
  • Pavicic T, Ruzicka T, Korting HC, Gauglitz G (2010)
    Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients. JDD 9: 690-697
  • Rzany B, Hilton S, Prager W, Hartmann V, Brandl G, Fischer TC, Gekeler O, Glöckner S, Gramlich G, Hartmann M, Lederman K, Luckner-Neugebauer J, Pavicic T, Stangl S, Walker T, Zenker S, Wolters M. (2010)
  • Expert guideline on the use of porcine collagen in aesthetic medicine. J Dtsch Dermatol Ges 8: 210-217
  • Pavicic T (2010)
    Die Kunst zu kombinieren: Injectables, ablative und andere ästhetische Verfahren. Plastische Chirurgie 4: 8-9
  • Pavicic T (2010)
    Die Kunst zu kombinieren: Injectables, ablative und andere ästhetische Verfahren. Face 4: 50-51
  • Pavicic T, Steckmeier S, Kerscher M, Korting HC (2009)
    Evidence-based cosmetics: concepts and applications in photoaging of the skin and xerosis. Wien Klin Wochenschr 121: 431-439
  • Pavicic T (2009)
    Fillers. An overwiev. Hautarzt 60: 233-244.
  • Pavicic T (2009)
    Filler – ein Überblick. J Ästhet Chir 2: 15-22.
  • Pavicic T (2009)
    Problem Cellulite. In: Fortschritte der praktischen Dermatologie und Venerologie, Bd. 21: 183-191. Hrsg.: Th Ruzicka, H Wolff, P Thomas, J Prinz. Springer, Berlin Heidelberg New York
  • Pavicic T, Steckmeier S, Kerscher M, Korting HC (2008)
    Evidence-Based Cosmetics: concept and applications for the targets cellulite, striae distensae und acne vulgaris. Geburtshilfe und Frauenheilkunde 10: 986-989.
  • Pavicic T, Wollenweber U, Farwick M, Korting HC (2007) Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosmet Sci 29:181-90.
  • Oppel T, Pavicic T, Kamann S, Bräutigam M, Wollenberg A (2007) Pimecrolimus cream (1%) Oppel efficacy in perioral dermatitis – results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 21:1175-80
  • Pavicic T, Wollenweber U, Farwick M, Korting HC (2007) Anti-microbial and -inflammatory activity and efficacy of phytosphingosine: an in vitro and in vivo study addressing acne vulgaris. Int J Cosm Scie 29: 181-190.
  • Pavicic T, Korting HC (2006) Xerosis and callus formation as a key to the diabetic foot syndrome: dermatologic view of the problem and its management. JDDG 11:935-941.
  • Pavicic T, Borelli C, Korting HC (2006)
    “Cellulite – das größte Hautproblem des Gesunden? Eine Annäherung”. JDDG 10: 861-870.
  • Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, Pavicic T, Boguniewicz M, Leung DYM (2006)
    “Cathelicidin deficiency predisposes to eczema herpeticatum”. J Allergy Clin Immunol 117: 836-841
  • Wollenberg A, Pavicic T, Oppel T, Decard S, Wetzel S (2005)
    “Epidermal dendritic cell phenotyping (EPDC) – 10 years’ experience”. JEADV 19: (Suppl. 2) 27.
  • Wollenberg A, Pavicic T, Wetzel S, Bräutigam M, Oppel T (2005)
    „Pimecrolimus 1% cream is effective in rosacea-like perioral dermatitis – results of a randomized, double-blinded, vehicle controlled clinical trial involving 40 patients“. JEADV 19: (Suppl. 2) 8.
  • Wollenberg A; Pavicic T; Wetzel S (2005)
    Eczema herpeticatum. In: Fortschritte der praktischen Dermatologie und Venerologie, Bd. 19. Hrsg.: G. Plewig, P. Kaudewitz, C. Sander. Springer, Berlin Heidelberg New York.
  • Wollenberg A; Kerschenlohr K; Pavicic T; Messmer EM (2004)
    Diagnostik und Therapie des Lidekzems. Hautarzt 55: 677-688
  • Eckstein F; Pavicic T; Nedbal S; Schmidt C; Wehr U; Rambeck W; Wolf E; Höflich A (2002)
    Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat Embryol 206: 139-148
  • Pavicic T; Eckstein F; Nedbal S; Wolf E; Hoeflich A (2001)
    “IGFBP-2 overexpression negatively regulates bone growth in vivo and suggests growth hormone action via local IGF”. Osteologie 10 (suppl 1), FV 8.5: 93

Lecturing

Topics

Consultant and Member in Advisory Boards on the topics:

  • aesthetic dermatology
  • fille
  • botulinum toxin
  • lasers
  • energy-based devices
  • combinationtreatments
  • cellulite
  • dermocosmetics

Clinical studies

  • Several monocentric and multicentric observative studies in aesthetic dermatology (botulinumtoxin, dermal filler, native hyaluronic acid, dermocosmetics, etc.)
  • Principal investigator in “Open-label, multicenter, uncontrolled, rater-blinded, post-market clinical follow-up [PMCF] study to confirm performance and safety of RADIESSE® (+) Lidocaine in the treatment of nasolabial folds, marionette lines, and/or cheek volume loss”
  • Principal investigator in “Open-label, multicenter, uncontrolled, rater-blinded, post-market clinical follow-up (PMCF) study to confirm performance and safety of Belotero® Soft Lidocaine and Belotero® Intense Lidocaine in the treatment of nasolabial folds, perioral fine lines and/or for lip volume enhancement”
  • Leading investigator in “Open label multicenter post-market clinical follow-up study to confirm the safety of Belotero® Volume Lidocain in temporal hollows and cheeks”
  • Principal investigator in “A prospective, open-label, multicenter, repeat-dose study to investigate the safety and efficacy of NT 201 (incobotulinumtoxinA) in the combined treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines), MRZ60201_3100_1
  • Principal investigator in “A phase iii, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of btx-a-hac ng in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of btx-a-hac ng following repeated treatments in this indication”
  • Principal investigator in “A phase II, double-blind, randomized, single treatment cycle, placebo and active comparator controlled study to assess the efficacy and safety of three dose levels of Dysport RU (20U, 50U and 75U) used for the improvement in appearance of moderate to severe glabellar lines (Y-52-52120-146), ()EUDRACT N° 2010-019085-82
  • Principal investigator in “Evaluation of Merz cheek scale following Radiesse cheek augmentation – A German trial” (P110594)
  • Principal investigator in “A phase II, double blind, randomised, placebo and active comparator controlled study to assess the safety and efficacy of three doses of Dysport RU (20 U, 50 U and 75 U) administered as a single treatment cycle to improve the appearance of moderate to severe glabellar lines“
  • Principal investigator in “A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD07743 for the improvement of Lateral Canthal Lines (crow’s feet) (RD.03.SPR.40131)
  • Principal Investigator in “Phase 3, multicenter, randomized, double-blind, placebo-controlled study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area”: (ATX-101-16)
  • Principal Investigator in monocentric investigator initiated phase-IV-study “A randomized, subject -blinded, controlled, single-center study of the safety and effectiveness of HYALACP, for the biorevitalisation of slight to moderate elastosis in dry and normal skin over 88 resp. 94 weeks“
  • Principal Investigator in multicenter clinical phase-IV-Study: MRZ 60201/GL/3002 (botulinum toxin)
  • Principal Investigator in the clinical phase-IV-Study: S194-401 (acne vulgaris)
  • Co-Investigator in the clinical phase-III-Study: MRZ 90030-0623/1 (dermal filler)
  • Sub-Investigator in the clinical phase-III-Study: MRZ 60201-0617/1 (botulinum toxin)
  • Co-Investigator in the clinical phase -III-Study “Efficacy and safety of adapalene 0.1% / benzoyl peroxide 2.5% gel compared to clindamycin 1% / benzoyl peroxide 5% gel in the treatment of acne vulgaris (RD.06.SPR.29058)
  • Co-Investigator in the clinical phase -III-Study “Open long term study without compare group to investigate the efficacy and safety of Tacrolimus ointment 0,1% in the treatment of atopic dermatitis (FG-506-06-21)”
  • Co-Investigator in the clinical phase -II-Study “Long term study to compare the efficacy and safety of a Tacrolimus ointment 0,1% regimen to vehicle based regimen administreted to control atopic dermatitis in adult patients; Control Study-Adults (FG-506-06-40)”
  • Co-Investigator in the clinical phase -III-Study „Four week long placebo-controlled monocentric study to evaluate the efficacy and safety of a 1% Pimecrolimus creme in rosacealike perioral dermatitis“
  • Co-Investigator in the clinical phase -III-Study „A 4 week, randomized, vehicle-controlled, multicenter evaluation of the efficacy and safety of a 1% Pimecrolimus creme in adult patients with perioral dermatitis followed by a 8 week treatment free observation phase in responders“

Medical career

Since 09/2014
Private Practice for Dermatology and Aesthetics of Dr Tatjana Pavicic

01/2012 – 08/2014
Head of Aesthetic and Laser Dermatology at the “Department and Clinics for Dermatology and Allergology of the Ludwig-Maximilian University, Munich”

01/2007 – 01/2012
Head of Aesthetic Dermatology at the “Department and Clinics for Dermatology and Allergology of the Ludwig-Maximilian University, Munich”

4/2008
Obtained title of medical specialist in dermatology and venereology

1/2005
Obtained licence to practise medicine

1/2004 – 08/2014 1/2004 – 08/2014
Doctor at the “Department and Clinics for Dermatology and Allergology of the Ludwig-Maximilian University, Munich”

Significant memberships

Since 11/2018
Treasurer of the Dermatologic Aesthetic Surgery International League (DASIL)

Since 05/2018
Honorary member of the French Society of dermatology

Since 10/2017
Board Member of the Dermatologic Aesthetic Surgery International  League (DASIL)

Since 10/2015
Board Member of the IMCAS Academy

Since 04/2015
Scientific Committee member of International Master Course on Aging Skin Congress

Since 07/2012
General Secretary of International Peeling Society (IPS)

08/2013-11/2017
Board Member of International Society of Dermatologic Surgery (ISDS)

10/2006-12/2015
Chairman of the Section Dermocosmetics of the Society for Dermopharmacy (GD)